Description: Kadcyla is an intravenous chemotherapy medication that combines trastuzumab, a monoclonal antibody targeting the HER2 protein, with emtansine, a chemotherapy drug. This combination is designed to specifically target cancer cells that overexpress the HER2 protein.

Composition: The active ingredients in Kadcyla are Trastuzumab and Emtansine. Each vial typically contains a specified amount of these components, often expressed in milligrams.

Uses: Kadcyla is indicated for the treatment of HER2-positive metastatic breast cancer in patients who have previously received trastuzumab and a taxane chemotherapy. It is designed to deliver both targeted therapy and chemotherapy to cancer cells.

How to Use: Kadcyla is administered by a healthcare professional through an intravenous infusion. The specific dosage and administration schedule are determined by the treating physician based on the patient’s specific condition.

Dosage: The dosage of Kadcyla can vary based on factors such as the type of breast cancer, the patient’s overall health, and other individual considerations. It is crucial to follow the prescribed dosage as directed by the healthcare provider.

Storage Conditions: Kadcyla should be stored according to the manufacturer’s instructions. Typically, it is stored in a cool, dry place, and precautions are taken to ensure its stability.

Mechanism of Action: Trastuzumab in Kadcyla targets the HER2 protein on cancer cells, while emtansine disrupts microtubule structures within the cells, inhibiting cell division and causing cell death.

Precautions:

• Patients with a known hypersensitivity to trastuzumab, emtansine, or any of the components in Kadcyla should not use it.
• Regular monitoring may be required during treatment to manage potential side effects.

Contraindications: Certain medical conditions or patient characteristics may contraindicate the use of Kadcyla. Consultation with a healthcare professional is necessary to assess individual contraindications.

Interactions: Kadcyla may interact with other medications or substances. It is crucial to inform the healthcare provider about all medications, including prescription, over-the-counter, and herbal supplements.

Overdose: In case of a suspected overdose, seek immediate medical attention. Overdose symptoms may vary, and professional medical assistance is required.

Side Effects: Common side effects of Kadcyla may include fatigue, nausea, headache, and musculoskeletal pain. Serious side effects can occur, and patients should promptly report any unusual or severe symptoms to their healthcare provider.

Always consult with a healthcare professional for the most accurate and personalized information regarding the use of Kadcyla (Trastuzumab Emtansine) or any other medication.